The Cancer Center of the Wake Forest University (CCWFU) is a multidisciplinary, interdepartmental cancer research facility. Research is organized into three divisions: 1. Division of Basic Sciences, 2. Division of Clinical Research, 3. Division of Cancer Control. Each is further subdivided into programs. The Division of Basic Sciences is composed of programs of research in Immunology and Molecular Genetics, Pharmacology, Cell Biology and Inflammation, Thrombosis and Experimental Radiation Oncology. The Division of Clinical Research has a major emphasis on technology transfer with introduction of new ideas from laboratory research to be applied in the diagnosis and treatment of cancer. These new leads stem from basic research conducted at the CCWFU, as well as at other cancer centers. Areas of special interest at the CCWFU include research in leukemia and other hematologic malignancies, breast, lung and colon cancer. In addition to clinical research conducted at the Center, a major clinical program is focused on the diffusion and application of new information into community practice through an organization known as the Piedmont Oncology Association (POA). The POA is a consortium of university and community oncologists throughout the 5-state regions of the Piedmont - North and South Carolina, Southern Virginia, Eastern Tennessee, and parts of Georgia. This Cancer Center-sponsored outreach program focuses on collaborative clinical trials and continuing education programs. In addition, the CCWFU brings protocols of a high priority fostered by the NCI and multi- university, national cooperative groups into the community. This approach offers community physicians and their patients the latest in cancer care. The Division of Cancer Control focuses on public education that will increase an awareness of cancer and will offer preventive measures and interventions for early detection. The Epidemiology Program will provide surveillance of cancer incidence in the region served by the Cancer Center in order to alert the faculty to the needs in education, prevention, and early detection. The CCWFU supports high technology core laboratories which facilitate cancer research. These include Tissue Culture, Electron Microscopy, Flow Cytometry, GC/MS, Pharmacology, NMR, Hybridoma, Oligonucleotide Synthesis Laboratory, Membrane Lipid Laboratory, and Protein Sequencing. Education in cancer is offered as a formal oncology curriculum to medical students, cancer research training for basic scientists at both the pre- and postdoctoral level and continuing education for physicians and nurses. The CCWFU has established a Cancer Patient Support Program which offers psychological supportive care to patients and their families and conducts research as to how this care might be optimized. Areas of future growth will include Molecular Genetics, Pharmacology, Immunology, Cell Biology and marrow transplantation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-18
Application #
3101281
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1976-03-01
Project End
1994-01-31
Budget Start
1990-02-01
Budget End
1991-01-31
Support Year
18
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
Schools of Medicine
DUNS #
041418799
City
Winston-Salem
State
NC
Country
United States
Zip Code
27106
Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323
Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594
Votanopoulos, Konstantinos Ioannis; Bartlett, David; Moran, Brendan et al. (2018) PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol 25:674-678
Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877
Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307
Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208
Gesell, Sabina B; Golden, Shannon L; Limkakeng Jr, Alexander T et al. (2018) Implementation of the HEART Pathway: Using the Consolidated Framework for Implementation Research. Crit Pathw Cardiol 17:191-200
Mao, Chengqiong; Qu, Ping; Miley, Michael J et al. (2018) P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. Biomater Sci 6:3063-3074
Bhatt, Nikunj B; Pandya, Darpan N; Rideout-Danner, Stephanie et al. (2018) A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents. Dalton Trans 47:13214-13221
Andrews, Rachel N; Caudell, David L; Metheny-Barlow, Linda J et al. (2018) Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury. Radiat Res 190:361-373

Showing the most recent 10 out of 548 publications